177 related articles for article (PubMed ID: 26752086)
1. Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.
Su T; Yang H; Fan Q; Jia D; Tao Z; Wan L; Lu X
Int J Pharm; 2016 Feb; 499(1-2):195-204. PubMed ID: 26752086
[TBL] [Abstract][Full Text] [Related]
2. Selective apoptotic killing of solid and hematologic tumor cells by bombesin-targeted delivery of mitochondria-disrupting peptides.
Cai H; Yang H; Xiang B; Li S; Liu S; Wan L; Zhang J; Li Y; Cheng J; Lu X
Mol Pharm; 2010 Apr; 7(2):586-96. PubMed ID: 20141196
[TBL] [Abstract][Full Text] [Related]
3. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery.
Liu S; Yang H; Wan L; Cai HW; Li SF; Li YP; Cheng JQ; Lu XF
Acta Pharmacol Sin; 2011 Jan; 32(1):79-88. PubMed ID: 21131998
[TBL] [Abstract][Full Text] [Related]
5. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
[TBL] [Abstract][Full Text] [Related]
6. Investigation of cancer cell lines for peptide receptor-targeted drug development.
Sun L; Luo J; Mackey LV; Morris LM; Franko-Tobin LG; LePage KT; Coy DH
J Drug Target; 2011 Sep; 19(8):719-30. PubMed ID: 21830941
[TBL] [Abstract][Full Text] [Related]
7. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
[TBL] [Abstract][Full Text] [Related]
8. Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics.
Okarvi SM; Jammaz IA
Nucl Med Biol; 2012 Aug; 39(6):795-804. PubMed ID: 22381782
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
10. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
11. Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension.
Li Q; Barrett A; Vijayakrishnan B; Tiberghien A; Beard R; Rickert KW; Allen KL; Christie RJ; Marelli M; Harper J; Howard P; Wu H; Dall'Acqua WF; Tsui P; Gao C; Borrok MJ
Bioconjug Chem; 2019 Apr; 30(4):1232-1243. PubMed ID: 30912649
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors.
Moody TW; Sun LC; Mantey SA; Pradhan T; Mackey LV; Gonzales N; Fuselier JA; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2006 Sep; 318(3):1265-72. PubMed ID: 16766720
[TBL] [Abstract][Full Text] [Related]
13. Bombesin analogue-mediated delivery preferentially enhances the cytotoxicity of a mitochondria-disrupting peptide in tumor cells.
Yang H; Cai H; Wan L; Liu S; Li S; Cheng J; Lu X
PLoS One; 2013; 8(2):e57358. PubMed ID: 23451211
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of anti-tumor activity of hybrid peptide in conjugation with carboxymethyl dextran via disulfide linkers.
Gaowa A; Horibe T; Kohno M; Tabata Y; Harada H; Hiraoka M; Kawakami K
Eur J Pharm Biopharm; 2015 May; 92():228-36. PubMed ID: 25801495
[TBL] [Abstract][Full Text] [Related]
15. Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
Zhang J; Bodenko V; Larkina M; Bezverkhniaia E; Xu T; Liao Y; Abouzayed A; Plotnikov E; Tretyakova M; Yuldasheva F; Belousov MV; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
J Control Release; 2024 Jun; 370():468-478. PubMed ID: 38697314
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin.
Kim H; Lee Y; Lee IH; Kim S; Kim D; Saw PE; Lee J; Choi M; Kim YC; Jon S
J Control Release; 2014 Mar; 178():118-24. PubMed ID: 24462899
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased
Feng J; Zhao C; Wang L; Qu L; Zhu H; Yang Z; An G; Tian H; Shou C
Theranostics; 2018; 8(8):2094-2106. PubMed ID: 29721065
[TBL] [Abstract][Full Text] [Related]
18. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors.
Schweinsberg C; Maes V; Brans L; Bläuenstein P; Tourwé DA; Schubiger PA; Schibli R; García Garayoa E
Bioconjug Chem; 2008 Dec; 19(12):2432-9. PubMed ID: 19053304
[TBL] [Abstract][Full Text] [Related]
19. Application of human pancreatic carcinoid BON cells for receptor-targeted drug development.
Sun L; Morris LM; Luo J; Mackey LV; Leslie JS; Franko-Tobin LG; Fuselier JA; LePage KT; Coy DH
J Drug Target; 2011 Sep; 19(8):666-74. PubMed ID: 21083509
[TBL] [Abstract][Full Text] [Related]
20. Conjugation to 10 kDa Linear PEG Extends Serum Half-Life and Preserves the Receptor-Binding Ability of mmTRAIL with Minimal Stimulation of PEG-Specific Antibodies.
Nie Q; Jia D; Yang H; Feng Y; Fan Q; Shi Q; Wan L; Lu X
Mol Pharm; 2017 Feb; 14(2):502-512. PubMed ID: 28029256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
